FDA Issues Warning Letters to Five Websites Selling Unapproved GLP-1 Drugs

The U.S. Food and Drug Administration (FDA) has sent warning letters to five online peptide vendors for illegally selling unapproved new drugs, including versions of semaglutide, tirzepatide, and retatrutide. Despite claims that products were 'for research purposes only,' the FDA found evidence that they were intended for human use, signaling a continued crackdown on the sale of unauthorized GLP-1s and similar products.